Evidence map›Paper›PMID 42531703›Full record

ArticleJournal of Crohn's & colitis2026

AI-based quantification of inflammatory extent for relapse prediction in ulcerative colitis: a prospective cohort study.

Yasuharu Maeda, Shin-Ei Kudo, Noriyuki Ogata, Kento Takenaka, Kaoru Takabayashi, Takanori Kuroki, Yurie Kawabata, Taishi Okumura, Tatsuya Sakurai, Yuta Kouyama and 8 more

Abstract read
In one paragraph

Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yasuharu MaedaDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.ORCID 0000-0002-4820-5959
Shin-Ei KudoDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Noriyuki OgataDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Kento TakenakaDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, 113-8519, Japan.ORCID 0000-0002-7861-8383
Kaoru TakabayashiCenter for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Takanori KurokiDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Yurie KawabataDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Taishi OkumuraDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Tatsuya SakuraiDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Yuta KouyamaDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Katsuro IchimasaDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Takemasa HayashiDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Toshiyuki BabaDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.
Haruhiko OgataCenter for Preventive Medicine, Keio University, Tokyo, 106-0041, Japan.
Kazuo OhtsukaEndoscopy Unit, Institute of Science Tokyo, Tokyo, 113-8519, Japan.
Yuichi MoriClinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, 0317 Norway.
Marietta IacucciAPC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, T12 YT20, Ireland.
Masashi MisawaDigestive Disease Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Kanagawa, 224-8503, Japan.

Funding

JSPS KAKENHI JP23K09537the Takeda Science Foundation, and The Japanese Foundation for Research and Promotion of Endoscopy
6 · The paper itself

Abstract

BACKGROUND AND

aimsEndoscopic remission is a key therapeutic goal in ulcerative colitis (UC); however, conventional indices focus on peak severity without accounting for the spatial extent of inflammation. We developed a deep learning-based score, Quantitative Ulcerative Colitis Assessment using Deep Learning (QUAD), and evaluated whether incorporating inflammatory extent improves relapse prediction in patients with UC in clinical remission. To our knowledge, no studies have examined whether artificial intelligence (AI)-derived assessment of inflammatory extent predicts clinical relapse.

methodsThis prospective cohort study evaluated relapse prediction over 24 months in patients with UC in clinical remission. The QUAD model assigns a score of 0-3 to each image quadrant, yielding a total score of 0-12. The model was trained on 84 743 images from 998 patients with UC across three centers. Still image-based validation and automated full-length video analysis were conducted to assess the impact of inflammatory extent on relapse prediction.

resultsClinical relapse occurred in 19.4% of patients with QUAD ≥ 4 compared with 5.2% of those with QUAD < 4 (P = .01), with an area under the curve (AUC) of 0.67 (95% confidence interval [CI]: 0.57-0.76). Notably, automated video-based analysis showed that distal inflammatory burden yielded the highest predictive performance, with analysis of the distal 10% segment achieving an AUC of 0.73 (95% CI: 0.62-0.85), compared with whole-colon assessment (AUC, 0.62; 95% CI: 0.48-0.76) and still image-based evaluation.

conclusionAI-augmented assessment integrating inflammatory severity and extent may provide complementary prognostic information beyond severity-based evaluation.

Indexed as

Artificial IntelligenceColitis, UlcerativeDeep LearningAdultColonoscopyFemaleHumansMaleMiddle AgedProspective StudiesRecurrenceSeverity of Illness Indexdeep learningendoscopic remissionrelapse prediction

Identifiers

PMID42531703
PMCPMC13423237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.